Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study
Article 2024 en
Authors
YK
Yoon Jun Kim
PM
Philippe Merle
RF
Richard S. Finn
Abstract
1 min read
The results of the real-world REFINE study confirmed the safety and effectiveness of regorafenib in a broad population of patients with uHCC. Of patients who received standard regorafenib dosing in REFINE, safety and efficacy findings were consistent with those reported in the RESORCE trial.
Richard S. Finn, Masatoshi Kudo, Heinz‐Josef Klümpen, Ho Yeong Lim, Philippe Merle, Masafumi Ikeda, Gianluca Masi, Catherine Frenette, Yoon Jun Kim, René Gerolami, Masayuki Kurosaki, Kazushi Numata, Julia Pisarenko, Kirhan Özgürdal, Shukui Qin
Ho Yeong Lim, Philippe Merle, Richard S. Finn, Catherine Frenette, Gianluca Masi, Masafumi Ikeda, Hong Zebger‐Gong, Sabine Fiala-Buskies, Kirhan Özgürdal, Masatoshi Kudo, Shukui Qin
Richard S. Finn, Philippe Merle, Masafumi Ikeda, Heinz‐Josef Klümpen, Gianluca Masi, Alessandro Granito, Ho Yeong Lim, Masatoshi Kudo, Shukui Qin, René Gerolami, Yi‐Hsiang Huang, Do Young Kim, Matthias Pinter, Naoya Kato, Masayuki Kurosaki, Kazushi Numata, Javeed Khan, Kirhan Özgürdal, Yoon Jun Kim
Philippe Merle, Ho Yeong Lim, Richard S. Finn, Masafumi Ikeda, Masatoshi Kudo, Catherine Frenette, Gianluca Masi, Yoon Jun Kim, René Gerolami, Masayuki Kurosaki, Kazushi Numata, Heinz‐Josef Klümpen, Hong Zebger‐Gong, Sabine Fiala-Buskies, Kirhan Özgürdal, Shukui Qin
Discussion(0)
No comments yet. Be the first to comment.